Immunogenicity and Safety Outcome of Homologous and Heterologous Prime-boost of Inactivated Vaccine and Replication-defective Viral Vectors Vaccine Against SARS-CoV2 among Hemodialysis Patients: An Observational Prospective Cohort Trial

Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand0 个研究点目标入组 130 人开始时间: 2022年5月16日最近更新: 2024年8月19日

试验速览

暂无简介。

•1.Participants at least age of 18-year-old who has maintenance hemodialysis with stable condition for at least 3 months before the enrollment
•2.Receives one of the following vaccine regimens
•a.Inactivated vaccine against SARS-CoV-2 (Sinovac, CoronaVac) regimen, or
•b.Replication-defective viral vectors against SARS-CoV-2 (AstraZeneca) regimen, or
•c.Heterologous prime boost of inactivated vaccine against SARS-CoV-2 (Sinovac, CoronaVac) followed by replication-defective viral vectors against SARS-CoV-2 (AstraZeneca)
•3.Provided informed consent

•1.Previously diagnosed COVID-19 in the past 90 days
•2.High-risk epidemiology history within 14 days before enrollment e.g., close contact with index cases or visiting/ living in outbreak area
•3.Has received other vaccine against SARS-CoV-2
•4.Participating in other vaccine clinical trial
•5.Receipt of blood products, blood components, or immunoglobulin within the past 90 days
•6.Receipt of attenuated live vaccine in the past 28 days
•7.Receipt of inactivated or subunit vaccines in the past 14 days
•8.Women in lactation, pregnancy, or planned pregnancy during the study period
•9.Solid and hematological malignancy
•10.Patients with known Human Immunodeficiency Virus (HIV) infection

发起方

Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand